Konrad Talbot

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9359393/publications.pdf

Version: 2024-02-01

40 papers

6,158 citations

28 h-index 288905 40 g-index

41 all docs

41 docs citations

41 times ranked

9563 citing authors

#	Article	IF	CITATIONS
1	Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. Journal of Clinical Investigation, 2012, 122, 1316-1338.	3.9	1,431
2	Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nature Neuroscience, 2016, 19, 1442-1453.	7.1	952
3	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease–associated Al² oligomers. Journal of Clinical Investigation, 2012, 122, 1339-1353.	3.9	697
4	Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia. Nature Medicine, 2006, 12, 824-828.	15.2	528
5	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. Journal of Clinical Investigation, 2004, 113, 1353-1363.	3.9	371
6	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. Journal of Clinical Investigation, 2004, 113, 1353-1363.	3.9	206
7	Caspase-3 Is Enriched in Postsynaptic Densities and Increased in Alzheimer's Disease. American Journal of Pathology, 2008, 173, 1488-1495.	1.9	171
8	Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin. Human Molecular Genetics, 2006, 15, 3041-3054.	1.4	141
9	Landscape of Conditional eQTL in Dorsolateral Prefrontal Cortex and Co-localization with Schizophrenia GWAS. American Journal of Human Genetics, 2018, 102, 1169-1184.	2.6	128
10	Neurodevelopment, neuroplasticity, and new genes for schizophrenia. Progress in Brain Research, 2005, 147, 319-345.	0.9	115
11	Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression. Human Molecular Genetics, 2009, 18, 3851-3863.	1.4	113
12	The nature, significance, and glucagonâ€ike peptideâ€1 analog treatment of brain insulin resistance in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, S12-25.	0.4	106
13	Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E962-70.	3.3	98
14	Measuring cell-type specific differential methylation in human brain tissue. Genome Biology, 2013, 14, R94.	13.9	92
15	Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs. Neurodegenerative Disease Management, 2014, 4, 31-40.	1.2	90
16	Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function. Hippocampus, 2012, 22, 230-240.	0.9	84
17	The schizophrenia susceptibility factor dysbindin and its associated complex sort cargoes from cell bodies to the synapse. Molecular Biology of the Cell, 2011, 22, 4854-4867.	0.9	74
18	Synaptic Dysbindin-1 Reductions in Schizophrenia Occur in an Isoform-Specific Manner Indicating Their Subsynaptic Location. PLoS ONE, 2011, 6, e16886.	1.1	71

#	Article	IF	Citations
19	Low sociability is associated with reduced size of the corpus callosum in the BALB/cJ inbred mouse strain. Brain Research, 2008, 1230, 211-217.	1.1	67
20	Mechanical Ventilation Triggers Hippocampal Apoptosis by Vagal and Dopaminergic Pathways. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 693-702.	2.5	66
21	The sandy (sdy) mouse: a dysbindin-1 mutant relevant to schizophrenia research. Progress in Brain Research, 2009, 179, 87-94.	0.9	65
22	A frontal variant of Alzheimer's disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex. Neurochemistry International, 2000, 37, 17-31.	1.9	62
23	Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics. Biochemical Pharmacology, 2020, 180, 114187.	2.0	57
24	Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia. Molecular Psychiatry, 2015, 20, 1091-1100.	4.1	56
25	MeCP2 Regulates the Synaptic Expression of a Dysbindin-BLOC-1 Network Component in Mouse Brain and Human Induced Pluripotent Stem Cell-Derived Neurons. PLoS ONE, 2013, 8, e65069.	1.1	38
26	Feline islands of calleja complex: II. Cholinergic and cholinesterasic features. Journal of Comparative Neurology, 1988, 275, 580-603.	0.9	34
27	Novel GLP-1R/GIPR co-agonist "twincretin―is neuroprotective in cell and rodent models of mild traumatic brain injury. Experimental Neurology, 2017, 288, 176-186.	2.0	34
28	Mutations in the BLOC-1 Subunits Dysbindin and Muted Generate Divergent and Dosage-dependent Phenotypes. Journal of Biological Chemistry, 2014, 289, 14291-14300.	1.6	33
29	Dysbindin-1 loss compromises NMDAR-dependent synaptic plasticity and contextual fear conditioning. Hippocampus, 2014, 24, 204-213.	0.9	28
30	Evidence that efferents from the basolateral amygdala innervate the dorsolateral neostriatum in rats. Neuroscience Letters, 1984, 44, 71-75.	1.0	23
31	Feline islands of calleja complex: I. Cytoarchitectural organization and comparative anatomy. Journal of Comparative Neurology, 1988, 275, 553-579.	0.9	21
32	Neuronal Activity-Induced Sterol Regulatory Element Binding Protein-1 (SREBP1) is Disrupted in Dysbindin-Null Miceâ€"Potential Link to Cognitive Impairment in Schizophrenia. Molecular Neurobiology, 2017, 54, 1699-1709.	1.9	17
33	Dysregulation of Specialized Delay/Interference-Dependent Working Memory Following Loss of Dysbindin-1A in Schizophrenia-Related Phenotypes. Neuropsychopharmacology, 2017, 42, 1349-1360.	2.8	17
34	EHD1 is a synaptic protein that modulates exocytosis through binding to snapin. Molecular and Cellular Neurosciences, 2010, 45, 418-429.	1.0	15
35	Brain energy failure in dementia syndromes: Opportunities and challenges for glucagonâ€ike peptideâ€1 receptor agonists. Alzheimer's and Dementia, 2022, 18, 478-497.	0.4	13
36	Insulin resistance and cognitive test performance in elderly adults: National health and nutrition examination survey (NHANES). Journal of the Neurological Sciences, 2018, 388, 97-102.	0.3	12

#	Article	IF	CITATIONS
37	Phospholipase pathway in Alzheimer's disease brains: decrease in Gαi in dorsolateral prefrontal cortex. Molecular Brain Research, 1999, 66, 188-190.	2.5	8
38	Newly identified precipitating factors in mechanical ventilation-induced brain damage: implications for treating ICU delirium. Expert Review of Neurotherapeutics, 2014, 14, 583-588.	1.4	7
39	Oxidative stress reduces levels of dysbindin-1A via its PEST domain. Neurochemistry International, 2014, 79, 65-69.	1.9	4
40	Effects of Lifestyle Factors on Cognitive Resilience: Commentary on "What This Sunny, Religious Town in California Teaches Us About Living Longer― Translational Stroke Research, 2020, 11, 161-164.	2.3	4